Monoclonal antibodies as disease modifying therapy in multiple sclerosis

Erin E. Longbrake, Becky J. Parks, Anne H. Cross

Research output: Contribution to journalArticlepeer-review

6 Scopus citations


Multiple sclerosis (MS), a demyelinating disease of the central nervous system, was untreatable until the mid- 1990s when beta-interferons and glatiramer acetate were introduced. These agents, while effective, were relatively nonspecific in action. Over the last 10 years, research has focused toward developing more targeted therapies for the disease. Monoclonal antibodies (mAbs) have been central to these efforts and many of the mAbs studied in MS have been singularly effective. We review here the 6 monoclonal antibodies that have been approved for MS or are in late-stage clinical trials, focusing on the drugs' efficacy and safety. Additionally, we review several monoclonal antibodies that were studied in MS but were found to be ineffective or even deleterious in this patient population.

Original languageEnglish
Article number390
JournalCurrent neurology and neuroscience reports
Issue number11
StatePublished - Nov 2013


  • Clinical trials
  • Diseasemodifying therapy
  • Monoclonal antibodies
  • Multiple sclerosis


Dive into the research topics of 'Monoclonal antibodies as disease modifying therapy in multiple sclerosis'. Together they form a unique fingerprint.

Cite this